Seoul, South Korea–based Orange Biomed operates out of Research Triangle Park, North Carolina in the U.S. The company currently has ongoing studies for its OBM rapid A1c test. It designed the glycated hemoglobin analyzer to function through single-cell analysis of red blood cells.
Co-founder Yeaseul Park describes OBM rapid A1c as a portable, guided, five-minute test. It requires only a single drop of blood to produce accurate results. The system integrates lab-level technology into portable devices, making healthcare accessible, accurate and affordable.
Orange Biomed featured in Drug Delivery Business News’ 11 diabetes startups you need to know. The company plans to unveil its latest technology at the 83rd Scientific Sessions of the American Diabetes Association (ADA) in June.
Get the full story at our sister site, Drug Delivery Business News.
